BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 11336587)

  • 1. Linezolid--a review of the first oxazolidinone.
    Norrby R
    Expert Opin Pharmacother; 2001 Feb; 2(2):293-302. PubMed ID: 11336587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic.
    Corti G; Cinelli R; Paradisi F
    Int J Antimicrob Agents; 2000 Dec; 16(4):527-30. PubMed ID: 11118873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linezolid: a review of its use in the management of serious gram-positive infections.
    Perry CM; Jarvis B
    Drugs; 2001; 61(4):525-51. PubMed ID: 11324682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.
    Falagas ME; Vardakas KZ
    Drug Saf; 2008; 31(9):753-68. PubMed ID: 18707190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linezolid.
    Narang M; Gomber S
    Indian Pediatr; 2004 Nov; 41(11):1129-32. PubMed ID: 15591662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid for the treatment of resistant gram-positive cocci.
    Bain KT; Wittbrodt ET
    Ann Pharmacother; 2001 May; 35(5):566-75. PubMed ID: 11346064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tedizolid: a new oxazolidinone antimicrobial.
    Kisgen JJ; Mansour H; Unger NR; Childs LM
    Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome.
    Vardakas KZ; Kioumis I; Falagas ME
    Curr Drug Metab; 2009 Jan; 10(1):2-12. PubMed ID: 19149508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of linezolid in children.
    Saiman L; Goldfarb J; Kaplan SA; Wible K; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S193-200. PubMed ID: 14520146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linezolid: the first oxazolidinone antimicrobial.
    Moellering RC
    Ann Intern Med; 2003 Jan; 138(2):135-42. PubMed ID: 12529096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linezolid: in infants and children with severe Gram-positive infections.
    Lyseng-Williamson KA; Goa KL
    Paediatr Drugs; 2003; 5(6):419-29; discussion 430-1. PubMed ID: 12765493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oxazolidinones as a new family of antimicrobial agent.
    Marchese A; Schito GC
    Clin Microbiol Infect; 2001; 7 Suppl 4():66-74. PubMed ID: 11688536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linezolid: an oxazolidinone antimicrobial agent.
    Fung HB; Kirschenbaum HL; Ojofeitimi BO
    Clin Ther; 2001 Mar; 23(3):356-91. PubMed ID: 11318073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
    Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid: pharmacokinetic characteristics and clinical studies.
    Bouza E; Muñoz P
    Clin Microbiol Infect; 2001; 7 Suppl 4():75-82. PubMed ID: 11688537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies.
    Rubinstein E; Isturiz R; Standiford HC; Smith LG; Oliphant TH; Cammarata S; Hafkin B; Le V; Remington J
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1824-31. PubMed ID: 12760854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Linezolid, an agent from a new class of antibiotics].
    Kuijper EJ; Schippers EF; Bernards AT
    Ned Tijdschr Geneeskd; 2004 Aug; 148(32):1577-81. PubMed ID: 15382556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of linezolid in the treatment of skin and soft tissue infections.
    Hau T
    Eur J Clin Microbiol Infect Dis; 2002 Jul; 21(7):491-8. PubMed ID: 12172739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.